Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (41-50 of 332) with videos related to

Pageof 34
Sort By:
International Psychogeriatrics|March 15, 2003
Butyrylcholinesterase: an important new target in Alzheimer's disease therapyNigel H Greig, Debomoy K Lahiri, Kumar Sambamurti
Current Alzheimer Research|June 25, 2005
Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blueNigel H Greig, Debomoy K Lahiri, Ezio Giacobini
CNS & Neurological Disorders Drug Targets|February 26, 2015
Current Update on Synopsis of miRNA Dysregulation in Neurological DisordersMohammad A Kamal, Gohar Mushtaq, Nigel H Greig
Handbook of Clinical Neurology|November 23, 2019
Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patientsMary V Seeman, Robert E Becker, Nigel H Greig
Royal Society Open Science|February 13, 2023
Molecular interaction of a putative inhibitor with bacterial SHV, an enzyme associated with antibiotic resistanceShazi Shakil, Syed M Danish Rizvi, Nigel H Greig
Antibiotics (Basel, Switzerland)|April 30, 2021
High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15Shazi Shakil, Syed M Danish Rizvi, Nigel H Greig
Journal of Biomolecular Structure & Dynamics|October 12, 2022
In depth molecular interaction analyses of the complex of a proposed CTXM-inhibitor bound to the bacterial enzymeShazi Shakil, Syed M Danish Rizvi, Nigel H Greig
British Journal of Pharmacology|April 24, 2012
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersIsidro Salcedo, David Tweedie, Yazhou Li, et al.
Current Alzheimer Research|February 10, 2009
Resurrecting clinical pharmacology as a context for Alzheimer disease drug developmentRobert E Becker, Latha K Unni, Nigel H Greig
Annals of Neurology|November 18, 2006
Tomographic visualization of cholinesteraseRodrigo O Kuljis, Sultan Darvesh, Nigel H Greig, et al.
Pageof 34

Showing results (41-50 of 332) with videos related to

Sort By:
Pageof 34
International Psychogeriatrics|March 15, 2003
Butyrylcholinesterase: an important new target in Alzheimer's disease therapyNigel H Greig, Debomoy K Lahiri, Kumar Sambamurti
Current Alzheimer Research|June 25, 2005
Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blueNigel H Greig, Debomoy K Lahiri, Ezio Giacobini
CNS & Neurological Disorders Drug Targets|February 26, 2015
Current Update on Synopsis of miRNA Dysregulation in Neurological DisordersMohammad A Kamal, Gohar Mushtaq, Nigel H Greig
Handbook of Clinical Neurology|November 23, 2019
Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patientsMary V Seeman, Robert E Becker, Nigel H Greig
Royal Society Open Science|February 13, 2023
Molecular interaction of a putative inhibitor with bacterial SHV, an enzyme associated with antibiotic resistanceShazi Shakil, Syed M Danish Rizvi, Nigel H Greig
Antibiotics (Basel, Switzerland)|April 30, 2021
High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15Shazi Shakil, Syed M Danish Rizvi, Nigel H Greig
Journal of Biomolecular Structure & Dynamics|October 12, 2022
In depth molecular interaction analyses of the complex of a proposed CTXM-inhibitor bound to the bacterial enzymeShazi Shakil, Syed M Danish Rizvi, Nigel H Greig
British Journal of Pharmacology|April 24, 2012
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersIsidro Salcedo, David Tweedie, Yazhou Li, et al.
Current Alzheimer Research|February 10, 2009
Resurrecting clinical pharmacology as a context for Alzheimer disease drug developmentRobert E Becker, Latha K Unni, Nigel H Greig
Annals of Neurology|November 18, 2006
Tomographic visualization of cholinesteraseRodrigo O Kuljis, Sultan Darvesh, Nigel H Greig, et al.
Pageof 34